Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation
NCT ID: NCT00884702
Last Updated: 2017-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
538 participants
OBSERVATIONAL
2009-04-16
2017-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The brain needs sleep to function normally, but the purpose of sleep is not understood. Brain activity decreases during sleep, so it may be that sleep is important to maintain, repair, or reorganize brain cells. In animals, the formation of brain proteins increases during sleep, and the same thing may happen in humans.
* There is also evidence that learning and memory are helped by sleep, and that the synthesis of proteins in the brain are involved.
Objectives:
* To examine the formation of proteins in the brain while people are awake, deprived of sleep, and during sleep.
* To look at the formation of proteins in the brain while awake or asleep and following learning a task.
Eligibility:
* Healthy volunteers between 18 and 28 years of age.
* Volunteers must not have psychiatric, neurologic, or sleep disorders or certain types of vision problems, and must be able to undergo imaging studies.
Design:
* Study Part I (protein formation in waking, sleep deprivation, and sleep):
* Participants will wear an actigraph (a unit to record motor activity) for 2 weeks prior to admission.
* Participants will have physical and psychological examinations, along with a blood sample.
* After admission participants will have three positron emission tomography (PET) scans to study protein formation and one magnetic resonance imaging (MRI) scan over the course of two days.
* Participants may be asked to stay awake for as long as 20 hours and will be monitored throughout.
* Participants will be able to sleep overnight after they complete the required scans and monitoring, and will be discharged the following morning.
* Study Part II (protein formation in waking and sleep combined with a learning task):
* Participants will wear an actigraph (a unit to record motor activity) for 2 weeks prior to admission.
* Participants will have physical and psychological examinations, along with a blood sample.
* After admission participants may be asked to stay awake for as long as 20 hours and will be monitored throughout.
* The next morning, participants will be trained to perform a computerized visual discrimination task, and will be tested 8 hours later (after sleep or after remaining awake) on the visual discrimination task.
* Some participants may have PET and MRI scans as part of the study.
* Participants will be able to sleep overnight after they complete the required tests and scans, and will be discharged the following morning.
* Participants will receive financial compensation for their participation in these studies.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
(9) Subjects with chronic indicated or non-indicated use of any medications which interfere with sleep architecture and/or learning trails will be excluded. Generally, we will prohibit the use of medications/agents (e.g. anti-histamines, benadryl, melatonin, cigarettes, chocolate, coffee, tea, caffeine drinks etc.), which have significant CNS penetration, are alerting, and/or disrupt physiologic sleep-wake cycles or sleep architecture, for the 72 hrs immediately preceding presentation for the study. To acclimatize subjects, we will encourage patients to discontinue or minimize the use of these agents/medications (e.g. less than or equal to 1 cup of coffee/day) at the time of initial screening (at the same time as actigraphy application, approximately 2 wks prior to the study).
Similarly, we ask subjects to minimize alcohol use for the 2 wks prior to the study and will discontinue alcohol use for the 72 hrs immediately preceding the study.
(10) Subjects who have used illicit drugs (marijuana, cocaine, heroin, etc.) within the immediate 2 wks preceding the study.
(11) Female subjects will be excluded if either clinical history is suspicious for, or laboratory evaluation is consistent with pregnancy.
(12) Subjects unwilling to undergo HIV testing, unless enrolling in Part IIa of the study.
(13) Subjects who test HIV positive.
(14) Patients with para- and/or ferro-magnetic prosthesis/implants/fragments in their body will be excluded from the study.
Exclusion Criteria
2. past or present diagnosis of psychiatric conditions (DSM-IV criteria) (many conditions (e.g. depression), may confound performance on learning trails or be associated with baseline sleep abnormalities),
3. chronic/degenerative/acquired neurologic disorder, (4) family history of genetically transmissible neurologic disorder,
(5) sleep disorders or medical conditions associated with chronically disordered sleep which may confound performance on learning trails or interfere with the sleep requirements of this study,
(6) visual impairments which may confound performance on learning trails,
(7) claustrophobic subjects,
18 Years
28 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carolyn B Smith, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Mental Health (NIMH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Armitage R. Microarchitectural findings in sleep EEG in depression: diagnostic implications. Biol Psychiatry. 1995 Jan 15;37(2):72-84. doi: 10.1016/0006-3223(94)00082-E.
Bishu S, Schmidt KC, Burlin T, Channing M, Conant S, Huang T, Liu ZH, Qin M, Unterman A, Xia Z, Zametkin A, Herscovitch P, Smith CB. Regional rates of cerebral protein synthesis measured with L-[1-11C]leucine and PET in conscious, young adult men: normal values, variability, and reproducibility. J Cereb Blood Flow Metab. 2008 Aug;28(8):1502-13. doi: 10.1038/jcbfm.2008.43. Epub 2008 May 21.
Boyle PJ, Scott JC, Krentz AJ, Nagy RJ, Comstock E, Hoffman C. Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest. 1994 Feb;93(2):529-35. doi: 10.1172/JCI117003.
McWhirter KK, Morrow AS, Lee BA, Bishu S, Zametkin AJ, Balkin TJ, Smith CB, Picchioni D. A PILOT STUDY ON THE ENCODING OF A PERCEPTUAL LEARNING TASK FOLLOWING SLEEP DEPRIVATION. Percept Mot Skills. 2015 Aug;121(1):80-93. doi: 10.2466/23.PMS.121c11x9. Epub 2015 Jul 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-M-0123
Identifier Type: -
Identifier Source: secondary_id
090123
Identifier Type: -
Identifier Source: org_study_id